Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Three Big Reasons to Own Johnson & Johnson (JNJ) Stock

Of course, there are more lucrative options out there. You could invest in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) or VIVUS, Inc. (NASDAQ:VVUS), which have developed obesity medications. Both Belviq and Qsymia, each company’s respective medicine, have been approved by the FDA and hold great potential for investors. But because of insurers being slow to pick up coverage, or labeling issues with the DEA, sales have yet to take off.

A much safer route would be to invest in Johnson & Johnson (NYSE:JNJ) stock. Although the company might not have a breakthrough medicine for obesity right now, it has enough cash to finance major research and development in the future. And the company also has a global reach, which becomes evermore important as the ills of Western living start to spread across the globe.

A Foolish approach
I’ve been investing in Johnson & Johnson (NYSE:JNJ) stock since August 2011. Since then, the stock has returned 45% — beating the market by 11 percentage points. But I still think any investor looking for exposure to health care would be wise to consider buying shares of Johnson & Johnson.

The article 3 Big Reasons to Own Johnson & Johnson Stock originally appeared on Fool.com and is written by Brian Stoffel.

Fool contributor Brian Stoffel owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of General Electric Company and Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.